前列腺癌筛查：欧洲随机前列腺癌筛查研究（ERSPC）和前列腺、肺癌、结直肠癌和卵巢癌筛查试验（PLCO）综述
Screening for Prostate Cancer: A Review of the ERSPC and PLCO Trials.
作者信息
Eckersberger Elisabeth, Finkelstein Julia, Sadri Helen, Margreiter Markus, Taneja Samir S, Lepor Herbert, Djavan Bob
机构信息
Department of Urology, School of Medicine, New York University New York, NY.
出版信息
Rev Urol. 2009 Summer;11(3):127-33.
Abstract
The advent of prostate-specific antigen (PSA) testing in the early 1980s revolutionized the diagnosis of prostate cancer. As a result of PSA testing, there has been a surge in the number of prostate cancer diagnoses. This review examines the results of 2 recent landmark trials that studied the effect of screening on prostate cancer mortality: the European Randomized Study of Screening for Prostate Cancer (ERSPC) and the US-based Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
摘要
20世纪80年代初前列腺特异性抗原（PSA）检测的出现彻底改变了前列腺癌的诊断方式。由于PSA检测，前列腺癌的诊断数量激增。本综述考察了两项近期具有里程碑意义的试验结果，这两项试验研究了筛查对前列腺癌死亡率的影响：欧洲前列腺癌筛查随机研究（ERSPC）和美国的前列腺、肺、结肠和卵巢（PLCO）癌筛查试验。
相似文献
1
Screening for Prostate Cancer: A Review of the ERSPC and PLCO Trials.前列腺癌筛查：欧洲随机前列腺癌筛查研究（ERSPC）和前列腺、肺癌、结直肠癌和卵巢癌筛查试验（PLCO）综述
Rev Urol. 2009 Summer;11(3):127-33.
3
The efficacy of prostate-specific antigen screening: Impact of key components in the ERSPC and PLCO trials.前列腺特异性抗原筛查的疗效：ERSPC 和 PLCO 试验中关键因素的影响。
Cancer. 2018 Mar 15;124(6):1197-1206. doi: 10.1002/cncr.31178. Epub 2017 Dec 6.
4
Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials.调和欧洲随机前列腺癌筛查研究（ERSPC）和前列腺、肺癌、结直肠癌和卵巢癌筛查试验（PLCO）中筛查对前列腺癌死亡率的影响。
Ann Intern Med. 2017 Oct 3;167(7):449-455. doi: 10.7326/M16-2586. Epub 2017 Sep 5.
5
Randomized trials of PSA screening.随机对照试验的 PSA 筛查。
Urol Oncol. 2025 Jan;43(1):23-28. doi: 10.1016/j.urolonc.2024.05.014. Epub 2024 Jun 25.
6
Screening for prostate cancer with the prostate-specific antigen test: a review of current evidence.用前列腺特异性抗原检测进行前列腺癌筛查：当前证据回顾。
JAMA. 2014 Mar 19;311(11):1143-9. doi: 10.1001/jama.2014.2085.
7
Large-scale randomized prostate cancer screening trials: program performances in the European Randomized Screening for Prostate Cancer trial and the Prostate, Lung, Colorectal and Ovary cancer trial.大规模随机前列腺癌筛查试验：欧洲前列腺癌随机筛查试验和前列腺、肺、结直肠癌和卵巢癌试验中的项目表现
Int J Cancer. 2002 Jan 10;97(2):237-44. doi: 10.1002/ijc.1588.
8
Screening for prostate cancer: reflecting on the quality of evidence from the ERSPC and PLCO studies.前列腺癌筛查：对欧洲前列腺癌筛查随机对照研究（ERSPC）和前列腺、肺癌、结直肠癌和卵巢癌筛查试验（PLCO）研究证据质量的反思
Recent Results Cancer Res. 2014;202:65-71. doi: 10.1007/978-3-642-45195-9_8.
9
The current state of prostate-specific antigen testing.前列腺特异性抗原检测的现状
JAAPA. 2016 Sep;29(9):51-3. doi: 10.1097/01.JAA.0000490955.33308.6e.
10
Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC).前列腺癌的检测：欧洲前列腺癌筛查随机研究（ERSPC）的影响
Can J Urol. 2005 Feb;12 Suppl 1:2-6; discussion 92-3.
引用本文的文献
1
Ten-Year Trends in Digital Rectal Exam Results and Prostate Cancer Detection: Insights from the PLCO Trial.直肠指检结果及前列腺癌检测的十年趋势：来自前列腺、肺癌、结直肠癌和卵巢癌筛查试验（PLCO）的见解
Res Rep Urol. 2025 Aug 29;17:309-320. doi: 10.2147/RRU.S542550. eCollection 2025.
2
The burden of prostate cancer in North Africa and Middle East, 1990-2019: Findings from the global burden of disease study.1990 - 2019年北非和中东地区前列腺癌负担：全球疾病负担研究结果
Front Oncol. 2022 Sep 13;12:961086. doi: 10.3389/fonc.2022.961086. eCollection 2022.
3
Attitudes Toward and Use of Prostate-Specific Antigen Testing Among Urologists and General Practitioners in Germany: A Survey.德国泌尿科医生和全科医生对前列腺特异性抗原检测的态度及使用情况：一项调查
Front Oncol. 2021 Jun 4;11:691197. doi: 10.3389/fonc.2021.691197. eCollection 2021.
4
Differences in Prostate Cancer Incidence and Mortality in Lower Saxony (Germany) and Groningen Province (Netherlands): Potential Impact of Prostate-Specific Antigen Testing.德国下萨克森州与荷兰格罗宁根省前列腺癌发病率和死亡率的差异：前列腺特异性抗原检测的潜在影响
Front Oncol. 2021 May 28;11:681006. doi: 10.3389/fonc.2021.681006. eCollection 2021.
5
General practitioners' approaches to prostate-specific antigen testing in the north-east of the Netherlands.荷兰东北部全科医生对前列腺特异性抗原检测的方法。
BMC Fam Pract. 2020 Dec 17;21(1):270. doi: 10.1186/s12875-020-01350-3.
6
PSA Based Biomarkers, Imagistic Techniques and Combined Tests for a Better Diagnostic of Localized Prostate Cancer.基于前列腺特异性抗原的生物标志物、影像学技术及联合检测以更好地诊断局限性前列腺癌。
Diagnostics (Basel). 2020 Oct 10;10(10):806. doi: 10.3390/diagnostics10100806.
7
Germline genetic variation in prostate susceptibility does not predict outcomes in the chemoprevention trials PCPT and SELECT.前列腺易感性中的胚系遗传变异不能预测 PCPT 和 SELECT 化学预防试验的结果。
Prostate Cancer Prostatic Dis. 2020 Jun;23(2):333-342. doi: 10.1038/s41391-019-0181-y. Epub 2019 Nov 27.
8
Accuracy of Tumour-Associated Circulating Endothelial Cells as a Screening Biomarker for Clinically Significant Prostate Cancer.肿瘤相关循环内皮细胞作为临床显著性前列腺癌筛查生物标志物的准确性
Cancers (Basel). 2019 Jul 27;11(8):1064. doi: 10.3390/cancers11081064.
9
Early detection of prostate cancer using prostate-specific antigen testing: an empirical evaluation among general practitioners and urologists.使用前列腺特异性抗原检测早期发现前列腺癌：全科医生和泌尿科医生的实证评估。
Cancer Manag Res. 2019 Apr 16;11:3079-3097. doi: 10.2147/CMAR.S193325. eCollection 2019.
10
Data analysis algorithm for the development of extracellular miRNA-based diagnostic systems for prostate cancer.基于细胞外 miRNA 的前列腺癌诊断系统开发的数据分析算法。
PLoS One. 2019 Apr 10;14(4):e0215003. doi: 10.1371/journal.pone.0215003. eCollection 2019.
本文引用的文献
1
Annual screening for prostate cancer did not reduce mortality from prostate cancer.前列腺癌年度筛查并未降低前列腺癌死亡率。
Evid Based Med. 2009 Aug;14(4):104-5. doi: 10.1136/ebm.14.4.104.
2
Prospective longitudinal comparative study of health-related quality of life in patients treated with radical prostatectomy or permanent brachytherapy for prostate cancer.前列腺癌根治性前列腺切除术或永久性近距离放射治疗患者健康相关生活质量的前瞻性纵向比较研究。
Acta Med Okayama. 2009 Jun;63(3):129-35. doi: 10.18926/AMO/31847.
3
Prostate cancer: to screen or not to screen?前列腺癌：筛查还是不筛查？
Nat Rev Urol. 2009 Jun;6(6):299-301. doi: 10.1038/nrurol.2009.92.
4
Cumulative incidence of false-positive results in repeated, multimodal cancer screening.重复多模式癌症筛查中假阳性结果的累积发生率。
Ann Fam Med. 2009 May-Jun;7(3):212-22. doi: 10.1370/afm.942.
5
Screening and prostate-cancer mortality in a randomized European study.一项欧洲随机研究中的筛查与前列腺癌死亡率
N Engl J Med. 2009 Mar 26;360(13):1320-8. doi: 10.1056/NEJMoa0810084. Epub 2009 Mar 18.
6
Mortality results from a randomized prostate-cancer screening trial.一项前列腺癌随机筛查试验的死亡率结果。
N Engl J Med. 2009 Mar 26;360(13):1310-9. doi: 10.1056/NEJMoa0810696. Epub 2009 Mar 18.
7
Psychological effects of a suspicious prostate cancer screening test followed by a benign biopsy result.可疑前列腺癌筛查结果随后活检结果为良性的心理影响。
Am J Med. 2004 Nov 15;117(10):719-25. doi: 10.1016/j.amjmed.2004.06.036.
8
Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results.3478例连续性患者接受耻骨后根治性前列腺切除术后的癌症进展和生存率：长期结果
J Urol. 2004 Sep;172(3):910-4. doi: 10.1097/01.ju.0000134888.22332.bb.
9
Preventing cancer, cardiovascular disease, and diabetes: a common agenda for the American Cancer Society, the American Diabetes Association, and the American Heart Association.预防癌症、心血管疾病和糖尿病：美国癌症协会、美国糖尿病协会和美国心脏协会的共同议程。
Circulation. 2004 Jun 29;109(25):3244-55. doi: 10.1161/01.CIR.0000133321.00456.00. Epub 2004 Jun 15.
10
Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer.前列腺特异性抗原筛查的提前期和过度诊断：来自欧洲前列腺癌筛查随机研究的估计
J Natl Cancer Inst. 2003 Jun 18;95(12):868-78. doi: 10.1093/jnci/95.12.868.
Zotero 插件